Xpovio® (selinexor) is now available in 3 new strength tablets, 40mg, 50mg, and 60mg, in addition to the 20mg strength.
Xpovio is indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma (MM) in adults who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.
It is also indicated in combination with bortezomib and dexamethasone for the treatment of adults with MM who have received at least 1 prior therapy. It is also approved for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
The additional strengths are intended to increase patient compliance and reduce pill burden. Xpovio is supplied in 12 dose presentations to help health care providers individualize the dosing and administration according to patient needs.
- Karyopharm announces Xpovio® (selinexor) is now available in additional strength tablets. [press release]. Newton, MA: Karyopharm Therapeutics Inc.; June 3, 2021.
- Xpovio [package insert]. Newton, MA: Karyopharm Therapeutics Inc.; 2021.
This article originally appeared on MPR